werewolf Therapeutics, Inc. announced the Investigational New Drug (IND) application clearance of JZP898 (formerly WTX-613), an engineered IFN INDUKINE molecule. The company continues to operate from a position of financial strength with a cash runway projected to carry through at least the fourth quarter of 2024. WTX-124: a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with KEYTRUDA(R) (pembrolizumab) in multiple solid tumors.

Additionally, the company are pleased that Jazz Pharmaceuticals has announced the Investigational New Drug ("IND") application clearance of JZP 898 (formerly WTX-614), an engineered IFN IND UKINE molecule. company continues to operate from aposition of financial strength with a cash run projected to carry through at least The fourth quarter of 2024. The company is progressing Study WTX-124x2101, its Phase 1/1b, multi-center, open-label clinical trial underwayvaluating WTX-124 as a monotherapy and in combination with KeyTRUDA(R) ("pembrolizumab") in patients with immunotherapy sensitive advanced or metastatic solid tumors who have failed standard of care, including prior checkpoint inhibitor therapy.

Enrollment is ongoing in monotherapy dose-escalation and combination therapy cohorts, and the Company anticipates reporting initial safety, tolerability, pharmacokinetics and biomarker data from monotherapy dose escalation in the fourth quarter of 2023. In 2022, company entered into an exclusive global collaborati and license agreement with Jazz Pharmacaceuticals under which company is responsible for certain pre-clinical development and other development activities with respect to JZP898. Jazz Pharmaceuticals recently disclosed that in July 2023, JZP898 received Investigational New Drug (IND).

The company also had restricted cash and cash equivalents of $21.2 million as of June 30, 2023, and March 31, 2023, respectively.